Replimune/$REPL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Replimune
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.
Ticker
$REPL
Sector
Primary listing
Employees
479
Headquarters
Website
Replimune Metrics
BasicAdvanced
$698M
-
-$3.60
0.42
-
Price and volume
Market cap
$698M
Beta
0.42
52-week high
$14.80
52-week low
$2.68
Average daily volume
4.1M
Financial strength
Current ratio
6.94
Quick ratio
6.802
Long term debt to equity
21.468
Total debt to equity
22.668
Interest coverage (TTM)
-36.94%
Profitability
EBITDA (TTM)
-287.16
Effective tax rate (TTM)
-0.17%
Management effectiveness
Return on assets (TTM)
-36.45%
Return on equity (TTM)
-73.44%
Valuation
Price to book
2.07
Price to tangible book (TTM)
2.07
Price to free cash flow (TTM)
-3.054
Free cash flow yield (TTM)
-32.74%
Free cash flow per share (TTM)
-2.928
Growth
Earnings per share change (TTM)
11.82%
3-year earnings per share growth (CAGR)
12.65%
What the Analysts think about Replimune
Analyst ratings (Buy, Hold, Sell) for Replimune stock.
Bulls say / Bears say
The FDA accepted Replimune’s Biologics License Application for RP1 plus nivolumab under Priority Review with a PDUFA date of July 22, 2025, supported by primary IGNYTE trial data demonstrating a 33.6% overall response rate and 27.6-month median duration of response in anti-PD-1 failed melanoma patients. (GLOBE NEWSWIRE)
As of June 30, 2025, Replimune held $403.3 million in cash, cash equivalents, and short-term investments, providing a runway into the fourth quarter of 2026 to fund clinical development and potential RP1 commercialization. (BioSpace)
The company advanced its RP2 program with plans to dose the first patient in a biliary tract cancer cohort in the second half of 2025 and ongoing Phase 2 trials in HCC under a collaboration with Roche, diversifying risk beyond RP1. (SEC Filing)
On July 22, 2025, the FDA issued a Complete Response Letter for RP1’s BLA, deeming the IGNYTE trial inadequate, which caused Replimune’s stock to plummet by 75% in a single day, underscoring significant regulatory risk. (Barron's)
The company identified material weaknesses in its IT general controls and is facing a class action lawsuit alleging federal securities law violations, raising concerns over governance and financial reporting integrity. (Panabee)
Replimune burned $192.3 million in cash from operations in fiscal year 2025, highlighting a high cash-burn rate that will necessitate additional funding absent revenue generation. (Panabee)
Data summarised monthly by Lightyear AI. Last updated on 3 Oct 2025.
Replimune Financial Performance
Revenues and expenses
Replimune Earnings Performance
Company profitability
Replimune News
AllArticlesVideos
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune
Business Wire4 weeks ago
REPL Deadline: Rosen Law Firm Encourages Replimune Group, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important September 22 Deadline in Securities Class Action First Filed by the Firm – REPL
Business Wire1 month ago
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune
Business Wire1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Replimune stock?
Replimune (REPL) has a market cap of $698M as of October 22, 2025.
What is the P/E ratio for Replimune stock?
The price to earnings (P/E) ratio for Replimune (REPL) stock is 0 as of October 22, 2025.
Does Replimune stock pay dividends?
No, Replimune (REPL) stock does not pay dividends to its shareholders as of October 22, 2025.
When is the next Replimune dividend payment date?
Replimune (REPL) stock does not pay dividends to its shareholders.
What is the beta indicator for Replimune?
Replimune (REPL) has a beta rating of 0.42. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.